Skip to main content
Hahn supports use of patient-focused endpoints in drugs, device trials
11/21/2019

President Donald Trump's nominee to lead the FDA, Stephen Hahn, stated that he plans to uphold the agency's approval standards for drugs and devices, and supports the use of patient-focused endpoints to expedite drug and medical device clinical trials. "I believe strongly in the importance of science, data and the law that have guided and should continue to guide the decision making at the FDA," says Hahn on drugs and medtech oversight.

Full Story: